G-CSF-induced decrease of the anti-granulocyte autoantibody levels in a patient with autoimmune granulocytopenia

Ann Hematol. 1997 Jul-Aug;75(1-2):59-64. doi: 10.1007/s002770050313.

Abstract

We present a case of an 81-year-old man with secondary autoimmune granulocytopenia in association with autoimmune thrombocytopenia. Treatment with granulocyte colony-stimulating factor (G-CSF) (5 micrograms/ kg/day s.c.) resulted in a rapid increase in the number of circulating granulocytes with a pronounced left shift. These changes were accompanied by up-regulation of the surface expression of Fc gamma RI (CD64) and Fc gamma RII (CD32) on the granulocytes. In addition, we noted a strong up-regulation of the Fc gamma RIII (CD16) and the activation markers CD11b and CD66b on the granulocytes. The increase in the number of circulating granulocytes was followed by a dramatic decrease in the level of cell-bound as well as circulating anti-granulocyte antibodies. It is hypothezised that the decrease in the level of cell-bound as well as circulating anti-granulocyte antibodies may be the result of an increased adsorption of the antibodies by the granulocytes.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aged, 80 and over
  • Agranulocytosis / blood
  • Agranulocytosis / drug therapy*
  • Agranulocytosis / immunology
  • Autoantibodies / blood*
  • Autoimmune Diseases / blood
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / immunology
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Granulocytes / immunology*
  • Humans
  • Male
  • Receptors, IgG / biosynthesis
  • Receptors, IgG / genetics
  • Thrombocytopenia / blood
  • Thrombocytopenia / drug therapy
  • Thrombocytopenia / immunology
  • Up-Regulation / drug effects

Substances

  • Autoantibodies
  • Receptors, IgG
  • Granulocyte Colony-Stimulating Factor